EA201400960A1 - Применение модафинила для лечения кокаиновой зависимости - Google Patents

Применение модафинила для лечения кокаиновой зависимости

Info

Publication number
EA201400960A1
EA201400960A1 EA201400960A EA201400960A EA201400960A1 EA 201400960 A1 EA201400960 A1 EA 201400960A1 EA 201400960 A EA201400960 A EA 201400960A EA 201400960 A EA201400960 A EA 201400960A EA 201400960 A1 EA201400960 A1 EA 201400960A1
Authority
EA
Eurasian Patent Office
Prior art keywords
modafinil
treatment
application
less
cocaine dependence
Prior art date
Application number
EA201400960A
Other languages
English (en)
Other versions
EA025692B1 (ru
Inventor
Паскаль Сюпли
Филипп Виве
Original Assignee
Дебрежа Э Ассосье Фарма
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дебрежа Э Ассосье Фарма filed Critical Дебрежа Э Ассосье Фарма
Publication of EA201400960A1 publication Critical patent/EA201400960A1/ru
Publication of EA025692B1 publication Critical patent/EA025692B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Настоящее изобретение относится к применению модафинила при кокаиновой зависимости. Используется правовращающий энантиомер модафинила (S-модафинил), у которого очень короткое время высвобождения (менее 1 ч, предпочтительно от 15 до 30 мин) и очень недолгий взбадривающий эффект (менее 4 ч, предпочтительно менее 2 ч). Его принимают перорально в составе фармацевтической композиции, причем разовая доза содержит от 25 до 200 мг, предпочтительно от 50 до 100 мг S-модафинила. Эта фармацевтическая композиция используется для заместительной терапии кокаиновой зависимости.
EA201400960A 2012-02-28 2013-02-25 Применение модафинила для лечения кокаиновой зависимости EA025692B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1200581A FR2987267B1 (fr) 2012-02-28 2012-02-28 Application du modafinil dans le traitement de substitution des cacainomanes
PCT/FR2013/000052 WO2013128088A1 (fr) 2012-02-28 2013-02-25 Application du modafinil dans le traitement des cocaïnomanes

Publications (2)

Publication Number Publication Date
EA201400960A1 true EA201400960A1 (ru) 2014-12-30
EA025692B1 EA025692B1 (ru) 2017-01-30

Family

ID=48083447

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400960A EA025692B1 (ru) 2012-02-28 2013-02-25 Применение модафинила для лечения кокаиновой зависимости

Country Status (33)

Country Link
US (1) US20150073055A1 (ru)
EP (1) EP2819655B1 (ru)
JP (1) JP6163169B2 (ru)
KR (1) KR101897855B1 (ru)
CN (1) CN104159575B (ru)
AR (1) AR090169A1 (ru)
AU (1) AU2013224831B2 (ru)
BR (1) BR112014020626A2 (ru)
CA (1) CA2863159C (ru)
CL (1) CL2014002203A1 (ru)
CY (1) CY1118166T1 (ru)
DK (1) DK2819655T3 (ru)
EA (1) EA025692B1 (ru)
ES (1) ES2593276T3 (ru)
FR (1) FR2987267B1 (ru)
HR (1) HRP20161165T1 (ru)
HU (1) HUE030737T2 (ru)
IL (1) IL234009B (ru)
IN (1) IN2014DN07831A (ru)
LT (1) LT2819655T (ru)
MX (1) MX348222B (ru)
NZ (1) NZ628009A (ru)
PH (1) PH12014501837A1 (ru)
PL (1) PL2819655T3 (ru)
PT (1) PT2819655T (ru)
RS (1) RS55238B1 (ru)
SG (1) SG11201405316WA (ru)
SI (1) SI2819655T1 (ru)
SM (1) SMT201600363B (ru)
TW (1) TWI626042B (ru)
UA (1) UA113301C2 (ru)
WO (1) WO2013128088A1 (ru)
ZA (1) ZA201405910B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105055404B (zh) * 2015-08-19 2017-07-18 四川大学 Hmgcs2抑制剂在制备治疗可卡因成瘾的药物中的用途
CN105055412B (zh) * 2015-08-20 2018-06-19 四川大学 Nampt抑制剂在制备治疗可卡因成瘾的药物中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
FR2771004B1 (fr) 1997-11-19 2000-02-18 Inst Curie Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse
US20010034373A1 (en) 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
AU1167702A (en) * 2000-10-11 2002-04-22 Cephalon Inc Compositions comprising modafinil compounds
US20040006532A1 (en) 2001-03-20 2004-01-08 David Lawrence Network access risk management
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
US7093476B2 (en) 2004-09-15 2006-08-22 Ut-Battelle, Llc Method for fabricating thin californium-containing radioactive source wires
WO2007013962A2 (en) * 2005-07-21 2007-02-01 Neurohealing Pharmaceuticals, Inc. Rapid onset and short term modafinil compositions and methods of use thereof
MX2009000391A (es) * 2006-07-12 2009-06-30 Elan Pharma Int Ltd Formulación de modafinilo en forma de nano-partículas.
EP1980240A1 (en) * 2007-04-11 2008-10-15 Cephalon France Lyophilized pharmaceutical compositions and methods of making and using same
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil

Also Published As

Publication number Publication date
LT2819655T (lt) 2016-10-25
EA025692B1 (ru) 2017-01-30
IN2014DN07831A (ru) 2015-04-24
CA2863159C (fr) 2018-06-12
HUE030737T2 (en) 2017-05-29
SMT201600363B (it) 2016-11-10
BR112014020626A2 (pt) 2017-06-27
UA113301C2 (xx) 2017-01-10
TWI626042B (zh) 2018-06-11
FR2987267A1 (fr) 2013-08-30
CA2863159A1 (fr) 2013-09-06
AU2013224831B2 (en) 2017-05-11
IL234009B (en) 2018-01-31
JP2015508805A (ja) 2015-03-23
AU2013224831A1 (en) 2014-08-21
ES2593276T3 (es) 2016-12-07
IL234009A0 (en) 2014-09-30
TW201340964A (zh) 2013-10-16
ZA201405910B (en) 2017-04-26
AR090169A1 (es) 2014-10-22
EP2819655B1 (fr) 2016-07-27
CL2014002203A1 (es) 2015-04-10
SI2819655T1 (sl) 2016-11-30
NZ628009A (en) 2015-07-31
FR2987267B1 (fr) 2015-01-16
JP6163169B2 (ja) 2017-07-12
KR20140135162A (ko) 2014-11-25
PH12014501837A1 (en) 2014-11-10
US20150073055A1 (en) 2015-03-12
PT2819655T (pt) 2016-10-14
PL2819655T3 (pl) 2017-01-31
EP2819655A1 (fr) 2015-01-07
CY1118166T1 (el) 2017-06-28
SG11201405316WA (en) 2014-11-27
DK2819655T3 (en) 2016-11-28
CN104159575A (zh) 2014-11-19
MX2014010237A (es) 2015-07-17
HRP20161165T1 (hr) 2016-11-04
RS55238B1 (sr) 2017-02-28
WO2013128088A8 (fr) 2014-09-12
MX348222B (es) 2017-06-05
WO2013128088A1 (fr) 2013-09-06
CN104159575B (zh) 2018-09-04
KR101897855B1 (ko) 2018-09-12

Similar Documents

Publication Publication Date Title
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201290919A1 (ru) Индазольные соединения и их применение
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
EA201491335A1 (ru) Бигуанидные композиции и способы лечения метаболических расстройств
EA201490516A1 (ru) Бифенилкарбоксиамиды в качестве ингибиторов rock-киназ
MD20150043A2 (ru) Ингибиторы гистон деметилаз
UA110612C2 (ru) Производные 1-амино-2-циклопропилетилбороновои кислоты
UA103915C2 (ru) Твердая лекарственная форма, которая содержит линаглиптин и ингибитор sglt2, и ее применение
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
UA109661C2 (ru) Фармацевтическая композиция, содержащая со-кристаллы трамадола и целекоксиба
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
MX382162B (es) Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
TW201613578A (en) Pharmaceutical combinations
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
EA201491500A1 (ru) Способы лечения фиброза
EA201500270A8 (ru) Фторметилзамещенные пирролкарбоксамиды
FI20115165A0 (fi) Terapeuttisia ja diagnostisia menetelmiä
BR112015028516A2 (pt) tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina
MX2016008968A (es) Compuestos organicos.
EA201400960A1 (ru) Применение модафинила для лечения кокаиновой зависимости

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ RU